In addition, SV2B expression was substantially higher than that of SV2A and SV2C in TFE3‐RCC tissues (Figure S11D, Supporting Information), suggesting that padsevonil inhibited tumor progression in TFE3‐RCC primarily by targeting SV2B. The gene discussed is TFE3; the disease is renal cell carcinoma.